Metastatic breast cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• HER2 193
• CDK4/6 49
• PIK3CA 24
• ESR1 11
• PD-L1 10
• BRCA1 2
• PI3K 13
• PARP 7
• BRCA2 2
• AKT 4
• PD-1 10
• STAT3 0
• PTEN 2
• TP53 0
• mTOR 5
• TROP2 4
• STING 0
• VEGF 4
• YAP 0
• PALB2 3
• MMP-9 0
• AR 0
• CXCR4 1
• EGFR 3
• HER3 4
• AMPK 0
• HDAC 1
• JAK 1
• CTNNB1 0
• FGFR 1
• PSMA 0
• ATM 0
• CD40 1
• EZH2 0
• FAK 0
• HIF-1 0
• MUC1 3
• PPAR 0
• BCL-2 1
• CD47 1
• COX-2 0
• ERK 0
• HSP90 0
• IGF1R 0
• IL-6 0
• MDM2 2
• MET 0
• MYC 0
• TNF 0
• B7-H3 1
• CCR5 0
• CSF1R 0
• CTLA-4 1
• JNK 0
• LAG-3 0
• MAPK 0
• NF1 0
• NRF2 0
• RANKL 0
• TIGIT 0

15 of 15+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

  Cardiff University· Cardiff, United Kingdom· EU contribution €260,348· until Apr 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Mapping antigenic niches of tumor-infiltrating B cells in triple-negative breast cancer (MAP-BC)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €252,180· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Re-wiring tumor immune-evasive plasticity with mRNA therapy (PLASTWIRE)

  Fundacio Institut Hospital del Mar D Investigacions Mediques· Barcelona, Spain· EU contribution €2,533,207· until Nov 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multispecific theranostic nano-engager platform (Nano-BITE)

  Institut Gustave Roussy· Villejuif, France· EU contribution €150,000· until May 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Femtosecond Laser Cross-Linking and Integrated Analytical Workflows for Decoding the Dynamic DNA–Protein Interactome (FEMTOMICS)

  Hawk Hochschule fur Angewandte Wissenschaft und Kunst Fachhochschule Hildesheim/Holzminden/Gottingen· Hildesheim, Germany· EU contribution €2,499,947· until Nov 2031· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  AtoMIc-based Quantum magnetometry meets Ultrasound for Medical Early Detection (MIstiQU-MED)

  Sorbonne Universite· Paris, France· EU contribution €150,000· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  INnovative Solutions for Pregnancy Intervention and Regulation: Translating Endometrial Science into Contraceptive Innovation and Ectopic Pregnancy Treatment (INSPIRE)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €2,500,000· until Oct 2031

• U.S. Department of Veterans Affairs · IK1

  Evaluating hypertension care delivery in Veterans with rheumatoid arthritis to improve cardiovascular disease prevention

  Durham Va Medical Center· Durham, United States· until Oct 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Biomimetic MXene Nanoplatforms for Targeted Combination Therapy of Triple-Negative Breast Cancer (BioMIX)

  Latvijas Universitate· Riga, Latvia· EU contribution €1,147,740· until Oct 2030· 12 countries

10 of 2,354 running projects, newest first. Listed amounts together: €289.4m + US$1.3bn.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Updated 2 May 2024

  “No subjects enrolled in the study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

  NCT05807126· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 21
• Organoids 7
• CRISPR-Cas Systems 4
• Gene Expression Profiling 63
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 5
• Proteomics 16
• Metabolomics 3
• Mass Spectrometry 1
• Flow Cytometry 9
• Immunohistochemistry 70
• Liquid Biopsy 19
• Circulating Tumor DNA 46
• Xenograft Model Antitumor Assays 109
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 64
• Machine Learning 30
• Deep Learning 23
• Cohort Studies 57
• Genome-Wide Association Study 1

• TP53 shapes tumour-specific immune phenotypes across breast, colorectal and kidney human cancers.

  J Mol Med (Berl), Nov 2026

• Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer.

  PLoS One, Oct 2026

• Mitochondrial transcript abundance in breast cancer circulating tumour cells may reflect both blood-derived transcripts and biological heterogeneity.

  Clin Exp Metastasis, Oct 2026

• Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.

  Int J Mol Sci, Sept 2026

• Spatial transcriptomics reveals atorvastatin modulates the tumor microenvironment to suppress breast cancer liver metastatic outgrowth.

  Neoplasia, Sept 2026

• 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

  Eur J Cancer, Sept 2026

• MicroRNA Expression Profiles Before and After Neoadjuvant Chemotherapy in Breast Cancer: Correlations with Molecular Subtypes, Pathological Response, and Clinical Timing-A Pilot Translational Study.

  Int J Mol Sci, Aug 2026

• Molecular and clinical predictors of NAC response and relapse in HR+/HER2- early breast cancer.

  Breast Cancer Res, Aug 2026

• Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.

  Clin Cancer Res, Aug 2026

• Integrated Transcriptomic Analysis Identifies Overlapping Gene Networks Between Breast Cancer Stem Cells and Paclitaxel-Primed Mesenchymal Stem Cell-Activated T Cells as Potential Immunotherapeutic Targets.

  Asian Pac J Cancer Prev, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.